SecBot SecBot
PRESS-RELEASE ·Filed Mar 17, 2026

ASND

Ascendis Pharma
BULLISH
Impact 7/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The comparable efficacy and favorable safety profile vs. daily therapy strengthens TransCon hGH’s differentiation as a once-weekly treatment, potentially driving adoption in Turner syndrome and supporting future label expansion. Traders should monitor progress in the Phase 3 HighLiGHts trial as a key catalyst.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$228.06
T+0 close · Mar 17, 2026 · via day close
Latest settled
−6.50%
T+60 · $213.23
Vs SPY
−16.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 17 $228.06entry
  2. T+1 · 8mo ago −0.28%α +1.11% · $227.41
  3. T+5 · 8mo ago −5.49%α −2.84% · $215.54
  4. T+20 · 7mo ago +5.99%α +1.68% · $241.71
  5. T+60 · 5mo ago −6.50%α −16.36% · $213.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma announced positive Week 52 results from its Phase 2 New InsiGHTS trial, showing that once-weekly TransCon hGH achieved annualized height velocity (9.05 cm/year) comparable to daily somatropin (9.04 cm/year) in children with Turner syndrome, with a similar safety profile and no cases of slipped capital femoral epiphysis. The data support ongoing Phase 3 HighLiGHts trial efforts for potential label expansion into growth hormone sufficiency indications.

Key Facts

  • TransCon hGH demonstrated annualized height velocity of 9.05 cm/year (LS mean) at Week 52, vs. 9.04 cm/year for daily somatropin
  • Trial included 49 prepubertal children with Turner syndrome aged 1–10 years
  • No occurrences of slipped capital femoral epiphysis (SCFE) in TransCon hGH group
  • Adverse events were mild to moderate; none led to discontinuation
  • Mean weekly dose: 0.22 mg/kg for TransCon hGH vs. 0.29 mg/kg for daily somatropin
  • Safety follow-up extended up to 143 weeks with comparable tolerability
  • Phase 3 HighLiGHts basket trial is now underway to support label expansion

Financial Impact

Potential for expanded market share in pediatric growth disorders; supports premium pricing and reimbursement positioning for once-weekly TransCon hGH

revenuemarket_sharepricing_power

Risk Factors

  • Regulatory approval not guaranteed despite positive Phase 2 data
  • Phase 3 trial may not replicate efficacy or safety findings
  • Competition from existing and emerging growth hormone therapies

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3257185

Track record

41 reports on ASND

Performance horizon

14 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202613d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 17, 2026